Evidence Examples

Previously reviewed claims, public side only.

Public-domain and synthetic examples showing how evidence movement, support, vulnerability, and uncertainty are assessed. These are illustrative specimens — private briefs carry the live decision context and source trail.

View Sample ClaimUse Baseline Check Validation Limits

Public Examples

Cardiorenal Public example OK

Cardiorenal evidence review: CKD progression and cardiovascular outcomes

Nonsteroidal mineralocorticoid receptor antagonist · Evidence Stability Review

CKD associated with Type 2 Diabetes

Supportable for current intended use, subject to existing caveats.

Sourced from FDA labels, pivotal trial publications, and two major guideline bodies. Two phase 3 trials (n=13,026 pooled) with consistent kidney and cardiovascular composite outcomes. Guideline recommendations strengthened from suggested to recommended (Level A) over the observation window.

Source timeline

2020-10 FIDELIO-DKD primary results published
2022-08 FDA label expansion to include CV indication
2024-05 KDIGO guidance elevated recommendation to Level A · Illustrative

Metabolic Public example Watch

Metabolic evidence example (T1D)

Illustrative · Regulatory Review

Type 1 Diabetes

Observable signals require monitoring within the stated decision window.

Historical example of evidence movement preceding formal regulatory recognition.

Source timeline

2022-11 First phase 3 readout in T1D population
2023-07 Advisory committee discussion · Illustrative
2024-02 Label expansion in comparator jurisdiction · Illustrative

Neurodegenerative Public example Review now

Sample Brief: Restriction Review for Amyloid-Directed Therapy in Early Alzheimer's Disease

Amyloid-directed therapy · Coverage Review

Early Alzheimer's Disease

Evidence movement warrants active review before the statement is relied on.

A broad coverage topic narrowed to one testable disputed claim, a one-page committee brief, and a source-bound audit appendix. Public-domain concepts only.

Source timeline

2021-06 Accelerated approval based on surrogate endpoint
2023-01 CMS National Coverage Determination issued
2024-07 Confirmatory trial CDR-SB results published · Illustrative

Neurodegenerative Public example Watch

Neurodegenerative review (Alzheimer's)

Illustrative · Safety Review

Alzheimer's Disease

Observable signals require monitoring within the stated decision window.

Historical example separating source-supported safety questions from public speculation.

Source timeline

2023-01 Safety signal flagged in post-market registry
2023-09 Regulatory request for enhanced monitoring · Illustrative
2024-12 Updated adverse-event meta-analysis · Illustrative

Metabolic Public example Review now

Semaglutide (illustrative specimen): from high-risk comorbidity settings to general obesity weight management

GLP-1 receptor agonist · Population Drift Review

Type 2 Diabetes / Obesity

Evidence movement warrants active review before the statement is relied on.

The same molecule is now being promoted in a broader population than the pivotal trials primarily studied. The move from high-risk diabetic or cardiovascular settings to general weight-management settings changes the strength of the supporting evidence and the review action.

Source timeline

2017-12 Initial FDA approval for Type 2 Diabetes
2021-06 FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
2024-03 SELECT trial cardiovascular outcomes published · Illustrative
2025-01 CMS coverage determination for obesity indication issued · Illustrative

Measurement Boundaries

Public examples are time-bounded and drawn from the public record. Private briefs carry the live decision context.
Live decision-context interpretation and source references are reserved for private briefs.
Every brief states what the record does and does not support. It does not call institutional outcomes.